Company intelligence / Profile preview

Umlaut

Heidelberg, Baden-Württemberg, Germanyumlautrecords.com ↗

Ownership: Private
Development stage: Other

Overview

Umlaut.bio has published preclinical results demonstrating that their small molecules can disrupt pathological signaling by interfering with key steps in tRNA modification synthesis. This approach selectively prevents the growth of cancer and proinflammatory cells by addressing a previously undrugged biochemical principle. No clinical trial results have been reported as of mid 2025

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Umlaut.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Umlaut.

Explore the full profile